🔹 Clinical trial transparency

Clinical trials are the most costly part of developing medicines, yet cost is not disclosed by companies. Transparency here is essential to fair pricing and ensuring the public return.
(See the excellent Transparency CORE toolkit by MSF) @rozscourse.bsky.social /7

#WHA78 @rozscourse.bsky.social

This meeting was the launch event for the great new @wemos.org @hai-org.bsky.social report on the implementation of the WHA transparency resolution - super helpful to see some progress and initiatives since 2019 but also how much more needs to be done:

www.wemos.org/wp-content/u...

@jamielove.bsky.social simply said: “fix this problem”

Now @dbdurisch.bsky.social @publiceye.ch showing how *2 days* after the @who.int transparency resolution was adopted in 2019, industry in Switzerland started a process to increase secrecy of drug prices - price transparency has got worse since then, not better

He argues for the need for standardization in *how* R&D costs are reported so this can be demanded from industry as part of health technology assessment

He argues for the need for standardization in *how* R&D costs are reported so this can be demanded from industry as part of health technology assessment

This work continues with plans to publish more of MSF's clinical trial costs - as well as publication of trial costs by others who are starting to use the toolkit we developed as part of this work: msfaccess.org/transparency...

Despite claims by industry that publishing R&D costs cannot be done, MSF is showing by doing that transparency in R&D spending can and must be done; it is critical to determine fair prices of medical products, equitable access, and public accountability.

MSF has led some groundbreaking clinical trials, including TB-PRACTECAL. Recognising the lack of transparency in R&D costs, MSF took the unprecedented step to commit to publishing the costs of the clinical trials that we are involved in; TB-PRACTECAL cost €33.9 million: msfaccess.org/call-transpa...

For decades the access to medicines community has called for more transparency in R&D costs. This is because the pharmaceutical industry continues to justify the high prices of medical products on high costs of R&D. These claims have never been backed up with evidence: msfaccess.org/secrets-cost...